BrainsWay Ownership

BRSYF Stock  USD 8.53  0.00  0.00%   
BrainsWay holds a total of 33.08 Million outstanding shares. BrainsWay shows 19.83 percent of its outstanding shares held by insiders and 1.11 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in pink sheets such as BrainsWay in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of BrainsWay, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BrainsWay. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more detail on how to invest in BrainsWay Pink Sheet please use our How to Invest in BrainsWay guide.

BrainsWay Pink Sheet Ownership Analysis

About 20.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.61. Some equities with similar Price to Book (P/B) outperform the market in the long run. BrainsWay recorded a loss per share of 0.22. The entity had not issued any dividends in recent years. The firm had 1:4 split on the 23rd of May 2011. Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel. Brainsway operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 118 people.The quote for BrainsWay is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on BrainsWay please contact Christopher Jako at 972 2 582 4030 or go to https://www.brainsway.com.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in BrainsWay Pink Sheet

When determining whether BrainsWay offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BrainsWay's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainsway Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainsway Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BrainsWay. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more detail on how to invest in BrainsWay Pink Sheet please use our How to Invest in BrainsWay guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Please note, there is a significant difference between BrainsWay's value and its price as these two are different measures arrived at by different means. Investors typically determine if BrainsWay is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BrainsWay's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.